RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard
neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced
esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune
checkpoint inhibition